NasdaqGS:BGNE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People’s Republic of China, the United States, and internationally. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has BeiGene's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BGNE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.5%

BGNE

1.7%

US Biotechs

2.3%

US Market


1 Year Return

132.8%

BGNE

39.7%

US Biotechs

17.2%

US Market

Return vs Industry: BGNE exceeded the US Biotechs industry which returned 37.9% over the past year.

Return vs Market: BGNE exceeded the US Market which returned 15.8% over the past year.


Shareholder returns

BGNEIndustryMarket
7 Day2.5%1.7%2.3%
30 Day16.5%-0.1%-4.6%
90 Day43.7%-3.4%7.4%
1 Year132.8%132.8%42.2%39.7%19.8%17.2%
3 Year154.5%154.5%14.6%9.1%37.4%28.3%
5 Yearn/a23.0%14.2%83.8%63.0%

Price Volatility Vs. Market

How volatile is BeiGene's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BeiGene undervalued compared to its fair value and its price relative to the market?

8.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: BGNE ($281.46) is trading above our estimate of fair value ($134.71)

Significantly Below Fair Value: BGNE is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BGNE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BGNE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BGNE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BGNE is overvalued based on its PB Ratio (8.7x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is BeiGene forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

51.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BGNE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BGNE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BGNE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BGNE's revenue (47.8% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: BGNE's revenue (47.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BGNE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has BeiGene performed over the past 5 years?

-61.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BGNE is currently unprofitable.

Growing Profit Margin: BGNE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BGNE is unprofitable, and losses have increased over the past 5 years at a rate of 61.1% per year.

Accelerating Growth: Unable to compare BGNE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BGNE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: BGNE has a negative Return on Equity (-54.89%), as it is currently unprofitable.


Next Steps

Financial Health

How is BeiGene's financial position?


Financial Position Analysis

Short Term Liabilities: BGNE's short term assets ($3.4B) exceed its short term liabilities ($551.2M).

Long Term Liabilities: BGNE's short term assets ($3.4B) exceed its long term liabilities ($805.6M).


Debt to Equity History and Analysis

Debt Level: BGNE's debt to equity ratio (12.5%) is considered satisfactory.

Reducing Debt: BGNE's debt to equity ratio has reduced from 12.9% to 12.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BGNE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BGNE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is BeiGene current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BGNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BGNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BGNE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BGNE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BGNE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

John Oyler (52 yo)

10.67yrs

Tenure

US$12,575,474

Compensation

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009. ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD12.58M) is about average for companies of similar size in the US market ($USD11.35M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
John Oyler
Co-Founder10.67yrsUS$12.58m4.8%
$ 1.2b
Xiaobin Wu
GM of China & President2.33yrsUS$9.13m0.038%
$ 9.7m
Xiaodong Wang
Co-Founder9.67yrsUS$4.00m0.99%
$ 252.7m
Heng Liang
CFO & Chief Strategy Officer5.17yrsUS$4.19m0.0025%
$ 638.7k
Jane Edna Huang
Chief Medical Officer of Hematology4yrsUS$3.61m0.014%
$ 3.6m
Daniel Maller
Vice President of Finance & Accountingno datano datano data
Craig West
Senior Director of Investor Relationsno datano datano data
Scott Samuels
Senior VP & General Counselno datano datano data
Diana Lee Francis
VP and Global Head of Quality & Regulatory Compliance3.25yrsno datano data
Luo Lusong
Head of Discovery Biology & Senior VP9.92yrsno datano data
Steven Young
Acting Head of Medicinal Chemistryno datano datano data
Wei Min
Head of Molecular Sciences and Senior Vice President4yrsno datano data

4.6yrs

Average Tenure

57yo

Average Age

Experienced Management: BGNE's management team is considered experienced (4.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Oyler
Co-Founder10.67yrsUS$12.58m4.8%
$ 1.2b
Xiaodong Wang
Co-Founder9.67yrsUS$4.00m0.99%
$ 252.7m
Thomas Malley
Independent Non-Executive Director & Member of the Scientific Advisory Committee0.50yrUS$372.47k0.034%
$ 8.6m
Michael Goller
Independent Non-Executive Director & Member of the Scientific Advisory Committee0.50yrUS$354.97k0.00079%
$ 201.0k
Donald Glazer
Independent Non-Executive Director7.5yrsUS$362.47k0.30%
$ 75.7m
Corazon Dating Sanders
Director & Member of Scientific Advisory Committee0.083yrno datano data
Anthony Hooper
Non Executive Director & Chairman of the Commercial Advisory Committee0.50yrno datano data
Jing-Shyh Su
Independent Non-Executive Director & Member of the Commercial Advisory Committee0.50yrUS$356.64k0%
$ 0
Yung-Cheng Chen
Independent Non-Executive Director & Member of the Commercial Advisory Committee4.5yrsUS$367.47k0%
$ 0
Ranjeev Krishana
Independent Lead Director & Member of the Commercial Advisory Committee0.50yrUS$357.47k0.00079%
$ 201.0k
Qingqing Yi
Independent Non-Executive Director & Member of the Scientific Advisory Committee0.50yrUS$370.80k0%
$ 0

0.5yrs

Average Tenure

57yo

Average Age

Experienced Board: BGNE's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BGNE insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.2%.


Top Shareholders

Company Information

BeiGene, Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BeiGene, Ltd.
  • Ticker: BGNE
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$25.446b
  • Shares outstanding: 90.41m
  • Website: https://www.beigene.com

Number of Employees


Location

  • BeiGene, Ltd.
  • No.30 Science Park Road
  • Zhong-Guan-Cun Life Science Park
  • Beijing
  • Beijing Province
  • 102206
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BGNENasdaqGS (Nasdaq Global Select)YesSPON ADS EACH REPR 13 ORDUSUSDFeb 2016
49BADB (Deutsche Boerse AG)YesSPON ADS EACH REPR 13 ORDDEEURFeb 2016
BGNE NBMV (Bolsa Mexicana de Valores)YesSPON ADS EACH REPR 13 ORDMXMXNFeb 2016
49BDB (Deutsche Boerse AG)Ordinary SharesDEEURAug 2018
6160SEHK (The Stock Exchange of Hong Kong Ltd.)Ordinary SharesHKHKDAug 2018
6160SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)Ordinary SharesHKHKDAug 2018
6160SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)Ordinary SharesHKHKDAug 2018

Biography

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People’s Republic of China, the United States, and i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/30 00:21
End of Day Share Price2020/09/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.